Physician profile
Chad Webster
NPI 1144220666
$185,056.72
in general payments reported to CMS, 2019-2025
31 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 80% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $3,795 · 2021: $4,313 · 2022: $157K · 2023: $2,931 · 2024: $1,579 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $4,268 · Food and Beverage: $1,091 · Travel and Lodging: $540 · Acquisitions: $277.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $4,267.84 |
| Food and Beverage | $1,091.03 |
| Travel and Lodging | $539.84 |
| Acquisitions | $277.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $161,337.18 | 2022-2025 | Motoband, Stropp |
| Crossroads Extremity Systems, LLC | $20,619.02 | 2019-2021 | |
| Gentleman Orthopedic Solutions | $691.68 | 2024-2025 | |
| Organogenesis INC. | $397.30 | 2019-2021 | |
| Biotissue Holdings INC. | $313.00 | 2023-2025 | |
| Arthrex, INC. | $287.47 | 2025 | |
| Stryker Corporation | $269.03 | 2019 | |
| Trilliant Surgical LLC. | $117.07 | 2019 | |
| Endologix LLC | $114.19 | 2019 | |
| Melinta Therapeutics, LLC | $113.86 | 2019 | |
| Wright Medical Technology, INC. | $109.36 | 2020 | |
| Horizon Therapeutics Plc | $88.60 | 2019 | |
| Boston Scientific Corporation | $64.70 | 2024 | Wavewriter Alpha Prime 16, Patient Trial Kit |
| Kerecis Limited | $50.13 | 2019-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Orthofix Medical, INC. | $47.99 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $42.95 | 2024-2025 | Exparel |
| Sandoz INC. | $41.22 | 2019 | |
| Treace Medical Concepts, INC. | $39.37 | 2025 | |
| Smith+Nephew, INC. | $38.66 | 2019-2020 | |
| Reprise Biomedical, INC. | $34.43 | 2024 | Miro3d |
| Acera Surgical, INC. | $33.89 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $32.96 | 2019-2024 | Nuzyra |
| Amgen INC. | $32.14 | 2025 | Krystexxa |
| Vertex Pharmaceuticals Incorporated | $27.85 | 2025 | |
| Bioventus LLC | $23.88 | 2024 | Exogen Ultrasound Bone Healing System |
| Zyla Life Sciences, INC. | $18.71 | 2019 | |
| Averitas Pharma INC. | $17.07 | 2023 | Qutenza |
| Osiris Therapeutics INC. | $15.83 | 2019 | |
| Grt US Holding, INC. | $14.40 | 2020 | |
| Cumberland Pharmaceuticals, INC. | $11.71 | 2019 | |
| Merck Sharp & Dohme LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,716.26 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.